ATNM vs ATOS

Actinium Pharmaceuticals, Inc. vs Atossa Therapeutics, Inc. — Valuation Comparison 2026

ATNM

Biotechnology
Actinium Pharmaceuticals, Inc.
Quality
5.3
out of 10
Value Trap
30
LOW
Price
$1.15
Last close
Models
9/13
Active
VS

ATOS

Biotechnology
Atossa Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$5.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ATNM Fair ValueATNM Upside ATOS Fair ValueATOS Upside
Bayesian DCF Intrinsic $0.95 -17.1% $3.40 -34.4%
First Chicago Scenario $0.63 -46.5% $14.39 +189.6%
ML-RIV Intrinsic $0.39 -65.7% $0.52 -90.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATNM vs ATOS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATNM vs ATOS — Which Stock Is More Undervalued?

ATNM scores higher with a 5.3/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Actinium Pharmaceuticals, Inc. (ATNM) and Atossa Therapeutics, Inc. (ATOS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATNM currently trades at $1.15 with a QOC of 5.3/10, while ATOS trades at $5.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).